RAP-219 hits primary endpoint in Phase 2 bipolar mania trial with statistically significant 3.1-point placebo-adjusted ...
AI can generate 100x more drug candidates, but trials still need real patients. The bottleneck has shifted, and most sponsors ...
FDA granted four DMD antisense oligonucleotide accelerated approvals on ~1 percentage-point dystrophin increases. With $967M ...
J&J's icotrokinra hit every UC endpoint in NEJM's Oct 2026 data, and the trial design choices behind that success are ...
FDA clears Haemonetics PerQseal Elite vascular closure system for large-bore arterial procedures, showing zero major ...
SpyGlass Pharma's Bimatoprost Pad-IOL demonstrates four-year durability in first-in-human trial, supporting two ongoing Phase ...
UP Oncolytics secures $2.5M NIH funding to advance engineered Zika virus glioblastoma therapy toward first human trial, ...
ArriVent's firmonertinib Phase 1b data published in Cancer Cell, targeting EGFR PACC mutations resistant to standard ...
IQVIA has made Veeva CTMS, eTMF, Study Startup and Site Connect enterprise standards across its clinical development studies, ...
Wearable devices show accuracy gaps in clinical trial endpoints, with sleep stage detection varying significantly across ...
Mabwell's 9MW2821 demonstrated a 30% response rate in ADC-pretreated triple-negative breast cancer patients, with an ...
EMA's CHMP recommended 6 new medicines and 5 label expansions in its Oct 12-15 cycle. Here's what daraxonrasib's pancreatic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results